{"id":470251,"date":"2021-04-01T18:03:30","date_gmt":"2021-04-01T22:03:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470251"},"modified":"2021-04-01T18:03:30","modified_gmt":"2021-04-01T22:03:30","slug":"genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/","title":{"rendered":"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BEIJING, April  01, 2021  (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit on Wednesday April 7<sup>th<\/sup>, 2021.<\/p>\n<p align=\"justify\">Interested parties may request more information by contacting their sales representative at SVB Leerink.<\/p>\n<p align=\"justify\">\n        <strong>About Genetron Holdings Limited<br \/><\/strong>Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g0isSkzvqD5wOcUqwbaMo8gl9ooqZzYDzUnJxkKBRfTbFHdVhYXF1-WOA4r9NprcdBmZQBu9rgGIgZGgQDZZud9HfHpgqGT6jeJuKL2V8YE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir.genetronhealth.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<br \/><\/strong>This press release contains forward-looking statements. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company\u2019s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as \u201cmay\u201d, \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cis\/are likely to\u201d or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company\u2019s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>\n        <u>US:<\/u><br \/>\n        <br \/>Hoki Luk<br \/>Head of Investor Relations<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4C5gjHP9nd1IHTECjW2sJFeOikJ8x4onXQrBIXHtJABLl7tYxQO0LoTFso9z6wDgUyb6SINPYEM944TJRsPo8-k6Zcj371RabcqI_l_OVIg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">hluk@genetronhealth.us<\/a><br \/>Phone: +1 (408) 891-9255<\/p>\n<p>David Deuchler, CFA<br \/>Managing Director | Gilmartin Group<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZA4UeYxRYuTsnsBikC7GBvh747Ey1EYdztg0x3aKdabCS_WJwu1xp0jpssNDvVbrqbXCWva420cpz6_O5eKZtJJltvwL_DhsCp3_2CwMw5A=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@genetronhealth.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c6fe896e-1d23-4f78-b8e3-558f8b4cc3c2\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit on Wednesday April 7th, 2021. Interested parties may request more information by contacting their sales representative at SVB Leerink. About Genetron Holdings LimitedGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470251","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEIJING, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit on Wednesday April 7th, 2021. Interested parties may request more information by contacting their sales representative at SVB Leerink. About Genetron Holdings LimitedGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company &hellip; Continue reading &quot;Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T22:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit\",\"datePublished\":\"2021-04-01T22:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/\"},\"wordCount\":373,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/\",\"name\":\"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=\",\"datePublished\":\"2021-04-01T22:03:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/","og_locale":"en_US","og_type":"article","og_title":"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit - Market Newsdesk","og_description":"BEIJING, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit on Wednesday April 7th, 2021. Interested parties may request more information by contacting their sales representative at SVB Leerink. About Genetron Holdings LimitedGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company &hellip; Continue reading \"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T22:03:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit","datePublished":"2021-04-01T22:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/"},"wordCount":373,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/","name":"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=","datePublished":"2021-04-01T22:03:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDU3NCM0MTAzMjg1IzIxOTAxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-to-present-at-the-svb-leerink-cyberx-series-liquid-biopsy-oncology-dx-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy &amp; Oncology Dx Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470251"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470251\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}